These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33397)

  • 1. [Dopamine-receptor stimulators and neuroleptic-induced dyskinesia (author's transl)].
    Ringwald E
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Nov; 11(6):294-8. PubMed ID: 33397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromocriptine in tardive dyskinesia.
    Häggström JE; Andersson U; Gunne LM
    Pharmacopsychiatria; 1982 Sep; 15(5):161-3. PubMed ID: 6129649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic measures in tardive dyskinesia].
    Tegeler J; Wöller W
    Fortschr Neurol Psychiatr; 1983 Jun; 51(6):203-26. PubMed ID: 6136457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The behavioral toxicity of bromocriptine in patients with psychiatric illness.
    Perovich RM; Lieberman JA; Fleischhacker WW; Alvir J
    J Clin Psychopharmacol; 1989 Dec; 9(6):417-22. PubMed ID: 2574194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of dopamine receptor agonists to reduce dopamine receptor number as treatment for tardive dyskinesia.
    Alpert M; Friedhoff AJ; Diamond F
    Adv Neurol; 1983; 37():253-8. PubMed ID: 6134444
    [No Abstract]   [Full Text] [Related]  

  • 6. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
    Bitton V; Melamed E
    J Clin Psychiatry; 1984 Jan; 45(1):28-30. PubMed ID: 6141157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of high single doses of bromocriptine in schizophrenic patients with elevated serum prolactin levels and extrapyramidal side effects associated with neuroleptic treatment (author's transl)].
    Ringwald E; Lustig A; Moscovici M; Spiegel R; Vamos E
    Pharmakopsychiatr Neuropsychopharmakol; 1980 Nov; 13(6):318-24. PubMed ID: 6111093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacological study.
    Rondot P; Bathien N
    Adv Neurol; 1987; 45():361-6. PubMed ID: 2881446
    [No Abstract]   [Full Text] [Related]  

  • 9. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?
    Jeste DV; Wyatt RJ
    J Clin Psychiatry; 1981 Dec; 42(12):455-7. PubMed ID: 6118358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of tardive and L-dopa-induced dyskinesias to antidepressants.
    el-Awar M; Freedman M; Seeman P; Goldenberg L; Little J; Solomon P
    Can J Neurol Sci; 1987 Nov; 14(4):629-31. PubMed ID: 3690436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Movement disorders with neuroleptic drug treatment.
    Tarsy D
    Psychiatr Clin North Am; 1984 Sep; 7(3):453-71. PubMed ID: 6148742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia].
    Lombertie ER; Durelle G; Fuseau A
    Ann Med Psychol (Paris); 1995 Oct; 153(8):531-4. PubMed ID: 8561400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy.
    Lieberman JA; Alvir J; Mukherjee S; Kane JM
    Arch Gen Psychiatry; 1989 Oct; 46(10):908-13. PubMed ID: 2572205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term treatment of tardive dyskinesia.
    Jus A; Jus K; Fontaine P
    J Clin Psychiatry; 1979 Feb; 40(2):72-7. PubMed ID: 33156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
    Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
    Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism.
    Wirshing WC; Freidenberg DL; Cummings JL; Bartzokis G
    J Clin Psychopharmacol; 1989 Dec; 9(6):407-11. PubMed ID: 2574192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study].
    Montastruc JL; Rascol O; Rascol A
    Rev Neurol (Paris); 1990; 146(2):144-7. PubMed ID: 2181588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of dyskinesias with tiapride (author's transl)].
    Kocher R; Hobi V
    Sem Hop; 1980 Dec 18-25; 56(47-68):2033-4. PubMed ID: 6109379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A therapeutic approach to tardive dyskinesia.
    Fahn S
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):19-24. PubMed ID: 2858474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.